Finding lifetime dividend growth is difficult. However, Motley Fool contributors Abbott Laboratories (ABT -1.99%), AbbVie (ABBV -0.95%), and Johnson & Johnson (JNJ -1.70%) feel they have uncovered outstanding dividend growth stocks you can buy and hold forever. These healthcare stocks have great dividend records. Read on to learn more about these.
ABT, or Abbott Laboratories, NYSE
Market Cap 203 billion
Abbott has routinely paid dividends since 1924 to shareholders despite wars, inflation, economic downturns, and other events. The quarterly compensation for Abbott has increased 150% in the past decade, from $0.22 in 2014 to $0.55 presently. Only because its valuation climbed by over 180% at that time does the healthcare stock’s yield not increase. When dividend reinvestment is considered, Abbott shareholders would have earned 250% over the past decade. We can therfire consider it a good bet as a lifetime dividend growth stock.
Abbott’s healthcare business is growing and has many alternatives. It grows slowly yet sustainably. Given its diverse product line—medicines, diagnostics, medical equipment, and nutrition—its operations seem sound. Without its COVID-19 testing branch, the company expects 10% organic sales growth this year. This could be the perfect investment for long-term income investors to buy and forget.
AbbVie
Market Cap $356 billion
This stock offers something for most investors. AbbVie has the potential. Skyrizi and Rinvoq, Humira alternatives, are doing well. The company’s breakthrough ovarian cancer drug, Elahere, is launching well. Botox earns billions annually. Sales of migraine drugs Ubrelvy and Qulipta are rising by double digits. AbbVie has 90 clinical development programs, including 50 mid to late-stage trials.
Johnson & Johnson Junior Bakiny Prosper
Market Cap 380 billion
Johnson & Johnson, a leading pharmaceutical corporation, credits several elements for its century-long existence. It is a potentially excellent income asset for risk-averse people. It has a history of making popular products independent of the market. Even in economic downturns, patients will prioritise prescriptions for their lives and health, keeping Johnson & Johnson’s company stable. The healthcare industry is protective for a reason.
The healthcare giant is hugely innovative; it sells drugs for infectious diseases, neurology, cancer, and immunology. The company’s pipeline is remarkable, with several dozen products in progress.
Johnson & Johnson has diversified its business. The company is a renowned medical device and pharmaceutical maker, and its AAA credit rating shows a healthy balance sheet. Despite ongoing legal and regulatory issues, the company should survive. Through its successful firm, Johnson & Johnson has raised its dividend for 62 years and will continue to do so for many more. Johnson & Johnson is a reliable dividend growth firm for long-term investors.
Contact Medallion Guarantee on 0203 985 9551.